Search - tctmd.com

Displaying 721 - 740 of 2029

Sort: Relevancy | Date

Presentation TCT 2014

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Juan F. Granada

September 16, 2014

Presentation TCT 2014

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Ulrich Hink

September 16, 2014

Presentation TCT 2014

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Laura Mauri

September 16, 2014

Presentation TCT 2014

Imaging to Guide BRS: Nice to Have or Must Have?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Evelyn S. Regar

September 16, 2014

Presentation TCT 2014

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Jonathan M. Hill

September 16, 2014

Presentation TCT 2014

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Kenya Brothers

September 16, 2014

Presentation TCT 2014

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Azeem Latib

September 16, 2014

Presentation TCT 2014

BRS Under Development V Biolute BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Dinesh Shah

September 16, 2014

Presentation TCT 2014

BRS Under Development IV The Lepu BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Yaling Han

September 16, 2014

Presentation TCT 2014

BRS Under Development III The XINSORB BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Junbo Ge

September 16, 2014

Presentation TCT 2014

BRS Under Development II Meril Life Sciences

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Martin B. Leon

September 16, 2014

Presentation TCT 2014

BRS Under Development I The Manli Mirage BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Teguh Santoso

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data V DREAMS: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Michael Haude

September 16, 2014

Presentation TCT 2014

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Stefan Verheye

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data IV ART-DIVA: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Jean Fajadet

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data III Amaranth: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Juan F. Granada

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data II From ReSolve to Fantom: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq

September 16, 2014

Presentation TCT 2014

TCT 610: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq

September 16, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

Sirolimus Nanocrystal Balloon-Based Delivery for Coronary DES-ISR

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Sameer I. Dani

September 16, 2014

Advertisement

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Imaging to Guide BRS: Nice to Have or Must Have?

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

BRS Under Development V Biolute BRS

BRS Under Development IV The Lepu BRS

BRS Under Development III The XINSORB BRS

BRS Under Development II Meril Life Sciences

BRS Under Development I The Manli Mirage BRS

BRS with Clinical Data V DREAMS: Differentiating Features and Clinical Update

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

BRS with Clinical Data IV ART-DIVA: Differentiating Features and Clinical Update

BRS with Clinical Data III Amaranth: Differentiating Features and Clinical Update

BRS with Clinical Data II From ReSolve to Fantom: Differentiating Features and Clinical Update

TCT 610: Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Sirolimus Nanocrystal Balloon-Based Delivery for Coronary DES-ISR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content